A spatial multi-omics study of combined small-cell lung cancer (cSCLC) provides new insight into tumor heterogeneity and highlights persistent challenges in diagnosis, particularly when only small biopsy samples are available.
cSCLC is a rare subtype, accounting for approximately 2 to 5 percent of small-cell lung cancer cases, and is defined by a mixture of small-cell and non-small cell lung cancer components within the same tumor. In routine practice, diagnosis is usually based on surgical specimens. However, in advanced disease, small biopsies may not capture all tumor components, contributing to underdiagnosis.
In this study, researchers analyzed 19 untreated cSCLC tumors using a combination of spatial whole-exome sequencing, spatial transcriptomics, and single-nucleus RNA sequencing. Across different tumor regions, they found a high level of shared mutations, supporting the idea that these mixed tumors arise from a single clone rather than separate cancers.
Importantly, the study showed that different tumor components can be arranged in separate regions or intermingled within the same tissue. These regions also differed in their surrounding microenvironment, including immune cell presence. Areas with small-cell features tended to show lower immune infiltration and reduced expression of antigen presentation markers. Fibroblast-rich bands were observed between tumor regions, suggesting a structural barrier that may further complicate sampling. These findings help explain why cSCLC can be difficult to diagnose from limited tissue. A biopsy may sample only one component of the tumor, leading to incomplete classification.
To address this, the researchers developed a mutation-based assay (“cSCLC Detector”) using a four-gene panel. The assay was tested in both tissue and circulating tumor DNA samples and showed improved sensitivity for detecting cSCLC compared with standard approaches. This type of tool may help support diagnosis when tissue samples are small or histologic findings are unclear.
The study also identified evidence of tumor plasticity, with transitions between adenocarcinoma and small-cell phenotypes and the presence of mixed cellular states. This variability may further complicate classification and testing.
Overall, the findings emphasize the need to consider tumor heterogeneity when diagnosing cSCLC and suggest that molecular assays may complement histopathologic evaluation, particularly in small biopsy or liquid biopsy settings.
Newsletters
Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.
